Illumina (ILMN) Set to Announce Earnings on Thursday

Illumina (NASDAQ:ILMN - Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, May 2nd. Analysts expect Illumina to post earnings of $0.03 per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.13. The business had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the firm posted $0.14 earnings per share. On average, analysts expect Illumina to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Illumina Price Performance

Shares of NASDAQ ILMN traded down $1.82 during midday trading on Thursday, reaching $121.05. 962,067 shares of the company were exchanged, compared to its average volume of 1,729,586. The stock's 50-day moving average price is $131.94 and its 200-day moving average price is $127.50. The stock has a market cap of $19.28 billion, a P/E ratio of -16.49 and a beta of 1.19. Illumina has a one year low of $89.00 and a one year high of $217.60. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26.

Insiders Place Their Bets

In other news, CEO Jacob Thaysen acquired 7,330 shares of Illumina stock in a transaction on Thursday, February 22nd. The stock was acquired at an average cost of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares of the company's stock, valued at approximately $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.17% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating in a research note on Tuesday, January 16th. TD Cowen cut shares of Illumina from an "outperform" rating to a "market perform" rating and set a $144.00 price objective on the stock. in a research note on Thursday, January 4th. Barclays boosted their price objective on shares of Illumina from $85.00 to $100.00 and gave the stock an "underweight" rating in a research note on Wednesday, April 10th. Stephens reissued an "overweight" rating and issued a $170.00 price objective on shares of Illumina in a research note on Wednesday, April 10th. Finally, StockNews.com raised shares of Illumina from a "hold" rating to a "buy" rating in a research note on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Illumina has a consensus rating of "Hold" and an average price target of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.